Evidence map›Paper›PMID 39848686›Full record

ArticleJournal for immunotherapy of cancer2025

PD-1 cis-targeted IL-2v in combination with radiotherapy inhibits lung cancer growth and remodels the immune microenvironment.

Céline Godfroid, Jackeline Romero, Sara Labiano, Chia-Hsien Chuang, Andrea Kelemen, Tania Wyss, Vincent Roh, Grégory Verdeil, Christian Klein, Laura Codarri Deak and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Céline GodfroidDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.ORCID http://orcid.org/0009-0007-0570-8840
Jackeline RomeroDepartment of Radiation Oncology, CHUV, Lausanne, Switzerland.
Sara LabianoPediatrics, Clínica Universidad de Navarra, Pamplona, Spain.
Chia-Hsien ChuangDepartment of Otolaryngology-Head and Neck Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Andrea KelemenDepartment of Otolaryngology-Head and Neck Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Tania WyssDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Vincent RohTDS-facility, SIB, Lausanne, Switzerland.
Grégory VerdeilDepartment of Oncology, University of Lausanne, Epalinges, Switzerland.
Christian KleinRoche Glycart AG, Schlieren, Switzerland.ORCID http://orcid.org/0000-0001-7594-7280
Laura Codarri DeakRoche Glycart AG, Schlieren, Switzerland.
Pablo UmañaRoche Glycart AG, Schlieren, Switzerland.
Genrich V TolstonogDepartment of Otolaryngology-Head and Neck Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Christine TrumpfhellerRoche Glycart AG, Schlieren, Switzerland.
Marie-Catherine VozeninSector of Radiobiology Applied to Radiotherapy, Radiation Oncology Service, Geneva University Hospital, Geneva, Switzerland.
Pedro J RomeroRoute de la Corniche 3B, Novigenix SA, 1066, Epalinges, Switzerland Pedro.romero@novigenix.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMore efficient therapeutic options for non-small cell lung cancer (NSCLC) are needed as the survival at 5 years of metastatic disease is near zero. In this regard, we used a preclinical model of metastatic lung adenocarcinoma (SV2-OVA) to assess the safety and efficacy of novel radio-immunotherapy combining hypofractionated radiotherapy (HRT) with muPD1-IL2v immunocytokine and muFAP-CD40 bispecific antibody.

methodsWe evaluated the changes in the lung immune microenvironment at multiple timepoints following combination therapies and investigated their underlying antitumor mechanisms. Additionally, we analyzed the tumor clonal heterogeneity upon the combination treatments to explore potential mechanisms associated with the lack of complete response.

resultsThe combination of HRT with muPD1-IL2v had a potent antitumor effect and increased survival in the SV2-OVA lung cancer model. Importantly, this combination therapy was devoid of measurable toxicity. It induced remodeling of the immune contexture through the increase of CD8

conclusionsWe demonstrated that HRT+muPD1-IL2v combination is a potent therapeutic strategy to delay tumor growth and increase survival in a metastatic lung cancer model, but additional studies are required to completely understand the resistance mechanisms associated with the lack of complete response in this model.

Indexed as

Interleukin-2Lung NeoplasmsProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAnimalsCell Line, TumorFemaleHumansMiceInterleukin-2Programmed Cell Death 1 Receptorantibodycombination therapycytokinelung cancerradiotherapy/radioimmunotherapy

Identifiers

PMID39848686
PMCPMC11759878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.